Graeme Lipper, MD
Dermatology · Danbury, CTNPI 1154371904
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,796 of the $15,853 with a category attached, or 74.4%. It is spread thinly across 32 manufacturers, the largest accounting for just 14.3%.
Across 700 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Promius Pharma LLC$2K
- AbbVie$2K
- Sanofi$2K
- LEO Pharma Inc.$2K
- Johnson & Johnson$857
- Pfizer$726
- plus $6K from 26 others
Across 46 payments — averaging $4345.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$116K
- Incyte Corporation$53K
- Boehringer Ingelheim$27K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
What the payments were for
- Consulting fees$1,68611%
- Speaking & faculty fees$2,00013%
- Travel & lodging$460%
- Food & beverage$11,79674%
- Education$3242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Promius Pharma LLC | 23 | $2,271 |
| AbbVie(2 entities) | 126 | $2,262 |
| Sanofi | 20 | $2,138 |
| LEO Pharma Inc. | 144 | $1,845 |
| Johnson & Johnson | 56 | $857 |
| Pfizer | 41 | $726 |
| Regeneron Healthcare Solutions, Inc. | 21 | $699 |
| Novartis | 30 | $525 |
| E.r. Squibb & Sons, L.L.C. | 29 | $506 |
| Galderma Laboratories, L.p. | 18 | $491 |
| Lilly USA, LLC | 27 | $462 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 20 | $400 |
| Almirall LLC | 23 | $337 |
| Sun Pharmaceutical Industries Inc. | 14 | $325 |
| UCB, Inc. | 14 | $299 |
| Amgen | 16 | $288 |
| Incyte Corporation | 11 | $264 |
| Dermavant Sciences, Inc. | 23 | $258 |
| Arcutis Biotherapeutics, Inc. | 11 | $230 |
| VYNE Pharmaceuticals Inc. | 6 | $130 |
| Prugen, Inc. Pharmaceuticals | 1 | $102 |
| Hydrofera LLC | 4 | $99 |
| Journey Medical Corporation | 3 | $51 |
| Organon | 6 | $51 |
| Boehringer Ingelheim | 2 | $37 |
| Sandoz | 2 | $37 |
| Mayne Pharma Commercial LLC | 2 | $35 |
| Verrica Pharmaceuticals Inc. | 2 | $35 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $30 |
| Medtronic | 1 | $29 |
| Mimedx Group, Inc. | 1 | $19 |
| EPI Health, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Promiseb Complete$2,126
- Sernivo$2,126
- TRIANEX 0.05%$2,126
- DUPIXENT$2,085
- NEMLUVIO$145
- Seysara$138
- ADBRY$124
How this compares
$15,853 in reported general payments places this provider in the 80th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $247,087 |
| TremfyaGuselkumab | 11 | $146,946 |
| Dupixent PenDupilumab | 30 | $110,525 |
| OtezlaApremilast | 12 | $53,497 |
| JubliaEfinaconazole | 15 | $11,326 |
| Metronidazole | 113 | $5,948 |
| Ketoconazole | 335 | $4,411 |
| Fluorouracil | 61 | $3,992 |
| Tacrolimus | 31 | $3,852 |
| Clobetasol Propionate | 97 | $3,778 |
| CiclopiroxCiclopirox Olamine | 228 | $3,283 |
| Pimecrolimus | 14 | $2,776 |
| Mupirocin | 337 | $2,390 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 94 | $2,042 |
| Triamcinolone Acetonide | 143 | $1,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $857 | $146,94611 claims |
| AmgenOtezla | $288 | $53,49712 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $400 | $11,32615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 dermatology providers in Connecticut.
Other dermatology in Danbury
- Mona GoharaDanbury$209K
- Jonathan ZirnDanbury$15K
- Alyssa MiceliDanbury$14K
- Grace FedermanDanbury$10K
- Michael PayetteCromwell$3.2M
- Bruce StroberCromwell$2.9M
- Brett KingFairfield$2.5M
- Mona ShahriariCromwell$2.2M
- Jeremy MossMadison$2M
- Brittany CraiglowFairfield$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.